Apyx Medical (APYX) Q2 2026 earnings review
Strong Core Growth, But Sequential Cash Burn Spikes
Apyx Medical delivered 22% YoY total revenue growth in Q2 2026, driven by a robust 28% expansion in its core Surgical Aesthetics segment. The successful launch of the AYON system continues to gain traction, bolstered by the new FDA 510(k) clearance for its power liposuction handpiece. However, while year-over-year profitability metrics improved, sequential trends show a sudden reversal: operating expenses jumped to $10.7M (from $8.8M in Q1) and operating cash burn spiked to $3.5M (from $0.6M in Q1). Management maintained full-year guidance, implicitly assuming the core segment will absorb the rapidly decaying OEM business.
🐂 Bull Case
The Q2 FDA 510(k) clearance and subsequent June shipment of the power liposuction handpiece turns AYON into a true all-in-one system, unblocking sales to surgeons who were waiting for this specific modality.
With an estimated 15 million+ U.S. adults having used GLP-1s, the growing pipeline of patients needing surgical intervention for rapid weight-loss induced skin laxity provides a massive structural tailwind for Renuvion and AYON.
🐻 Bear Case
Despite management's previous claims of a 'lean operating structure,' Q2 operating expenses sequentially surged by $1.9M to $10.7M, and net cash used in operations jumped from $0.6M in Q1 to $3.5M in Q2.
The legacy OEM segment reversed from 14% growth in Q1 to a 12% decline in Q2. Full-year guidance implies a severe 33% contraction, forcing Surgical Aesthetics to work harder just to pull total company revenue higher.
⚖️ Verdict: ⚪
Neutral. The top-line transition is working perfectly: Apyx is successfully trading low-margin, shrinking OEM revenue for high-margin, growing AYON revenue. However, the sudden sequential spike in cash burn and operating expenses creates execution risk around management's claim that existing cash will last through 2027.
Key Themes
Power Liposuction Unlock Accelerates AYON Penetration
Apyx secured an expanded FDA 510(k) clearance for the AYON Body Contouring System to include a reusable power liposuction handpiece. The company initiated targeted commercial shipments in June. This is a critical catalyst: management previously noted that many surgeons were deferring purchases until this specific modality was available. This addition essentially makes AYON a completely integrated body contouring workstation.
Sequential Reversal in Cash Discipline
While Apyx highlights YoY improvements (Q2 Net Loss narrowed to $3.2M from $3.8M), the sequential narrative contradicts the company's 'lean structure' thesis. Operating expenses spiked to $10.7M (up from $8.8M in Q1). More concerningly, cash used in operations jumped to $3.5M, driven by working capital changes, compared to just $0.6M burn in Q1. This places intense pressure on H2 execution to maintain the runway through 2027.
International Expansion Gaining Traction
International sales provided a solid secondary growth engine, growing 24.4% YoY to $4.5M in Q2. Following the Q1 momentum heavily driven by the South Korea launch, continued adoption of Renuvion generators globally is helping diversify the revenue base away from purely domestic capital spending cycles.
OEM Segment in Structural Decline
The OEM segment (historically driven by partners like Symmetry Surgical) is decelerating rapidly. After showing an unexpected 14% bounce in Q1, revenue reversed to a 12% decline in Q2 ($1.5M). Management explicitly warned that this trend will persist over time. The FY26 guidance implicitly requires OEM revenue to drop to a mere ~$1.4M quarterly run-rate in H2.
Tariff Drag Masked by Favorable Mix
Gross margins expanded to 63.9% (from 62.3% YoY). However, management noted that this was achieved despite ongoing tariffs that began in H2 2025. The margin expansion was entirely rescued by a favorable product mix shift toward the higher-margin Surgical Aesthetics segment and specific product mix within OEM. If Surgical Aesthetics growth slows, the tariff impact will become highly visible on the bottom line.
Other KPIs
Improved year-over-year from a $2.0M loss, but sequentially deteriorating from the $0.3M loss posted in 26Q1 and the $0.7M profit in 25Q4. The sequential decline reflects the higher SG&A and salary costs absorbed during the quarter.
Decreased from $31.7M at the end of FY25 and $31.1M at the end of 26Q1. The accelerated burn in Q2 ($3.5M used in operations) was attributed to working capital changes. Management still projects this balance will yield cash through 2027.
Guidance
Stable. The reaffirmed guidance implies roughly 12.6% YoY growth at the midpoint. Because H1 2026 revenue is $26.3M, Apyx must deliver $33.2M in H2 to hit the midpoint, requiring a meaningful back-half acceleration.
Stable. Implies ~20% YoY growth from $45.3M in FY25. With $23.1M achieved in H1, the segment needs to generate roughly $31.4M in H2, relying heavily on the conversion of the power liposuction handpiece limited launch into broad commercial volume.
Stable but deteriorating. Reaffirmed guidance implies a 33% YoY decline from FY25's $7.5M. Having recorded $3.25M in H1, the implied H2 OEM revenue is only ~$1.75M, reflecting a stark phase-out of this division.
Stable. Having spent $19.5M in H1, Apyx has $25.5M in Opex allowance for H2. Given the Q2 sequential jump to $10.7M, keeping the full year under $45M appears highly feasible, but prevents any aggressive scaling of sales & marketing headcount.
Key Questions
Working Capital Burn
Operating cash burn spiked to $3.5M in Q2, primarily attributed to working capital changes. What specific components of working capital (inventory build for AYON, accounts receivable delays) drove this, and will it reverse in H2?
Sequential Expense Jump
Operating expenses grew by $1.9M sequentially from Q1 to Q2. How much of this was one-time costs associated with the AYON power liposuction launch versus structural increases in baseline salaries and SG&A?
AYON Power Liposuction Mix
Now that the power liposuction handpiece is shipping, what percentage of the H2 Surgical Aesthetics guidance relies on upgrading existing Renuvion customers versus acquiring net-new accounts who were waiting for this feature?
OEM Wind-Down Strategy
With OEM revenue implied to drop severely in H2 based on the full-year $5M guide, are you purposefully sunsetting these legacy contracts, and what happens to the fixed overhead currently supporting that segment?